Novartis' Acute Heart Failure Drug Fails in Late-Stage Study

Novartis AG NVS recently suffered a setback on the announcement of disappointing data from a phase III study RELAX AHF 2 on pipeline candidate serelaxin RLX030 A look at Novartis share price movement over the past one year shows that the stock has underperformed the Zacks